• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Secukinumab distributes into dermal interstitial fluid of psoriasis patients as demonstrated by open flow microperfusion.

作者信息

Dragatin Christian, Polus Florine, Bodenlenz Manfred, Calonder Claudio, Aigner Birgit, Tiffner Katrin Irene, Mader Julia Katharina, Ratzer Maria, Woessner Ralph, Pieber Thomas Rudolf, Cheng Yi, Loesche Christian, Sinner Frank, Bruin Gerard

机构信息

Health - Institute for Biomedicine and Health Sciences, Joanneum Research Forschungsgesellschaft m.b.H., Graz, Austria.

Novartis Institutes for BioMedical Research, Basel, Switzerland.

出版信息

Exp Dermatol. 2016 Feb;25(2):157-9. doi: 10.1111/exd.12863. Epub 2015 Nov 23.

DOI:10.1111/exd.12863
PMID:26439798
Abstract
摘要

相似文献

1
Secukinumab distributes into dermal interstitial fluid of psoriasis patients as demonstrated by open flow microperfusion.如开放流动微灌注所示，司库奇尤单抗可分布至银屑病患者的真皮间质液中。
Exp Dermatol. 2016 Feb;25(2):157-9. doi: 10.1111/exd.12863. Epub 2015 Nov 23.
2
Secukinumab in plaque psoriasis--results of two phase 3 trials.司库奇尤单抗治疗斑块状银屑病的两项 3 期临床试验结果。
N Engl J Med. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9.
3
Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis.司库奇尤单抗在中度至重度银屑病患者中的群体药代动力学建模
J Clin Pharmacol. 2017 Jul;57(7):876-885. doi: 10.1002/jcph.876. Epub 2017 Mar 8.
4
Secukinumab (AIN457) for the treatment of psoriasis.司库奇尤单抗（AIN457）用于治疗银屑病。
Expert Rev Clin Immunol. 2015;11(11):1177-88. doi: 10.1586/1744666X.2015.1095092. Epub 2015 Oct 1.
5
Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE).司库奇尤单抗注射液/笔治疗银屑病的疗效、安全性和实用性：一项随机对照试验（JUNCTURE）。
J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1082-90. doi: 10.1111/jdv.12751. Epub 2014 Sep 22.
6
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.司库奇尤单抗在清除中重度斑块状银屑病患者皮肤方面优于乌司奴单抗：CLEAR，一项随机对照试验。
J Am Acad Dermatol. 2015 Sep;73(3):400-9. doi: 10.1016/j.jaad.2015.05.013. Epub 2015 Jun 17.
7
Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.司库奇尤单抗治疗中重度斑块状银屑病的疗效和安全性：一项随机、双盲、安慰剂对照的 II 期剂量范围研究。
Br J Dermatol. 2013 Feb;168(2):412-21. doi: 10.1111/bjd.12110. Epub 2013 Jan 18.
8
Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).预充式注射器给药司库奇尤单抗治疗银屑病的疗效、安全性和使用结果：一项随机对照试验（FEATURE）。
Br J Dermatol. 2015 Feb;172(2):484-93. doi: 10.1111/bjd.13348. Epub 2014 Dec 11.
9
Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.司库奇尤单抗诱导和维持治疗中重度斑块状银屑病：一项随机、双盲、安慰剂对照、Ⅱ期方案探索研究。
Br J Dermatol. 2013 Feb;168(2):402-11. doi: 10.1111/bjd.12112.
10
Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy.静脉注射司库奇尤单抗治疗需要激素免疫抑制治疗的非感染性葡萄膜炎的疗效和安全性。
Ophthalmology. 2015 May;122(5):939-48. doi: 10.1016/j.ophtha.2014.12.033. Epub 2015 Jan 29.

引用本文的文献

1
Translational Pharmacokinetics of Icotrokinra, a Targeted Oral Peptide that Selectively Blocks Interleukin-23 Receptor and Inhibits Signaling.艾考特金拉的转化药代动力学，一种选择性阻断白细胞介素-23受体并抑制信号传导的靶向口服肽。
Dermatol Ther (Heidelb). 2025 Jul 8. doi: 10.1007/s13555-025-01454-7.
2
Lateral Flow-Based Skin Patch for Rapid Detection of Protein Biomarkers in Human Dermal Interstitial Fluid.基于横向流的皮肤贴片，用于快速检测人体真皮间质液中的蛋白质生物标志物。
ACS Sens. 2024 Nov 22;9(11):5792-5801. doi: 10.1021/acssensors.4c00956. Epub 2024 Oct 25.
3
Characterization of Inflammatory Mediators and Metabolome in Interstitial Fluid Collected with Dermal Open Flow Microperfusion before and at the End of Dupilumab Treatment in Atopic Dermatitis.
特应性皮炎患者接受度普利尤单抗治疗前后真皮开放式流动微灌注法获取的细胞间液中炎症介质和代谢组学特征
J Proteome Res. 2024 Aug 2;23(8):3496-3514. doi: 10.1021/acs.jproteome.4c00153. Epub 2024 Jul 10.
4
The oral IRAK4 inhibitors zabedosertib and BAY1830839 suppress local and systemic immune responses in a randomized trial in healthy male volunteers.口服 IRAK4 抑制剂 zabedosertib 和 BAY1830839 在健康男性志愿者的随机试验中抑制局部和全身免疫反应。
Clin Transl Sci. 2024 Mar;17(3):e13771. doi: 10.1111/cts.13771.
5
Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Moderate-to-Severe Psoriasis.中重度银屑病治疗的临床药代动力学和药效学考虑因素。
Clin Pharmacokinet. 2024 Feb;63(2):137-153. doi: 10.1007/s40262-023-01341-4. Epub 2024 Jan 27.
6
Comparative Study of Dermal Pharmacokinetics Between Topical Drugs Using Open Flow Microperfusion in a Pig Model.猪模型中使用开放流动微灌注法对局部用药物的皮肤药代动力学进行比较研究。
Pharm Res. 2024 Feb;41(2):223-234. doi: 10.1007/s11095-023-03645-3. Epub 2023 Dec 29.
7
Comparison of monoclonal antibody disposition predictions using different physiologically based pharmacokinetic modelling platforms.使用不同生理基于药代动力学建模平台的单克隆抗体处置预测比较。
J Pharmacokinet Pharmacodyn. 2024 Dec;51(6):639-651. doi: 10.1007/s10928-023-09894-4. Epub 2023 Nov 12.
8
Dermal open flow microperfusion for PK-based clinical bioequivalence studies of topical drug products.用于局部用药品基于药代动力学的临床生物等效性研究的皮肤开放流动微灌注法
Front Pharmacol. 2022 Nov 22;13:1061178. doi: 10.3389/fphar.2022.1061178. eCollection 2022.
9
Advanced Online Monitoring of In Vitro Human 3D Full-Thickness Skin Equivalents.体外人3D全层皮肤等效物的高级在线监测
Pharmaceutics. 2022 Jul 8;14(7):1436. doi: 10.3390/pharmaceutics14071436.
10
Minimal Physiologically-Based Pharmacokinetic (mPBPK) Metamodeling of Target Engagement in Skin Informs Anti-IL17A Drug Development in Psoriasis.基于最小生理药代动力学（mPBPK）的皮肤靶点参与元建模为银屑病抗IL17A药物开发提供信息。
Front Pharmacol. 2022 Apr 25;13:862291. doi: 10.3389/fphar.2022.862291. eCollection 2022.